At Inte:Ligand, Sharon oversees all operations, implementing strategic initiatives to enter new markets and incorporating innovation paradigms to fulfill customer needs. She is a champion of transparent communication and customer driven innovation, resulting in user friendly, high performance, innovative software solutions that are distinctive to Inte:Ligand's products. Sharon also oversees ongoing consulting research projects involving development of predictive models, design and… Show more At Inte:Ligand, Sharon oversees all operations, implementing strategic initiatives to enter new markets and incorporating innovation paradigms to fulfill customer needs. She is a champion of transparent communication and customer driven innovation, resulting in user friendly, high performance, innovative software solutions that are distinctive to Inte:Ligand's products. Sharon also oversees ongoing consulting research projects involving development of predictive models, design and identification of bioactive molecules for industry clients.Inte:Ligand is currently involved in the NeuroDeRisk IMI-2 project, developing an in silico toolbox for derisking drugs for neurotoxic adverse events (https://neuroderisk.eu/in-silico-toolbox/).Inte:Ligand GmbH, is an Austrian company that develops computer aided molecular design software and provides research consulting services to pharmaceutical and life science industries in 88 countries worldwide. LigandScout, recognized worldwide as the best 3D-pharmacophore and virtual screening tool on the market, is a molecular design platform used to rapidly establish in silico SAR, provide reliable medicinal chemistry decision support and identify bioactive molecules. It incorporates high performance cloud computing with unique efficient interfaces to ensure high productivity. Inte:Ligand also offers products for building novel fragment based virtual chemical libraries (ilib:diverse), AI based solutions for molecule design and predictions, the ILPharmDB, useful for target prediction, compound activity and selectivity profiling including robust toxicity and neurotoxic adverse outcomes predictions. Show less

Sharon has been teaching courses in the Pharmaceutical Chemistry and Pharmacy programs at the University of Vienna since 2014. She is regular faculty member, also teaching in the Master in Drug Discovery and Development, a new study program that was initiated in October 2017. Her main course topics include Innovation in Preclinical Drug Discovery, Hit and Lead Identification in Chemistry Driven Drug Discovery, 3D-Pharmacophore and Computer Aided Drug Design Methodologies and Case Studies in… Show more Sharon has been teaching courses in the Pharmaceutical Chemistry and Pharmacy programs at the University of Vienna since 2014. She is regular faculty member, also teaching in the Master in Drug Discovery and Development, a new study program that was initiated in October 2017. Her main course topics include Innovation in Preclinical Drug Discovery, Hit and Lead Identification in Chemistry Driven Drug Discovery, 3D-Pharmacophore and Computer Aided Drug Design Methodologies and Case Studies in Preclinical Drug Discovery. The University of Vienna, located in Vienna Austria, was founded in 1365 and is the oldest university in the German-speaking world. It offers 181 degree programs and has more than 90,000 students enrolled. Show less

Sharon was a Research Scientist at the National Institutes of Health (NIH), specializing in computer aided design, protein modeling and biophysical methods to develop small molecule and peptide derivatives targeting opioid receptors. Her work culminated in more than 130 research publications and patents covering opioid inventions as well as collaborations with scientists in Japan, Italy and the US. Her work was recognized by several NIH awards and fellowships (UCSF-Kollman, JSPS-Kobe, Japan)… Show more Sharon was a Research Scientist at the National Institutes of Health (NIH), specializing in computer aided design, protein modeling and biophysical methods to develop small molecule and peptide derivatives targeting opioid receptors. Her work culminated in more than 130 research publications and patents covering opioid inventions as well as collaborations with scientists in Japan, Italy and the US. Her work was recognized by several NIH awards and fellowships (UCSF-Kollman, JSPS-Kobe, Japan) as well as invitations to lecture at universities and scientific conferences. Show less